Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Cellular stress induces erythrocyte assembly and promotes microangiopathy
Dec 19, 2018
Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms...
The need for ultra high field magnetic resonance imaging
Dec 17, 2018
MRI is a noninvasive imaging technology that is known for its superior soft tissue contrast and ability to provide...
The most advanced software for preclinical imaging research
Nov 7, 2018
Modern imaging laboratories hosting PET/MR instruments profit from the fully integrated common imaging platform...
Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs
Oct 12, 2018
Drug delivery by nanocarriers (NCs) has long been stymied by dominant liver uptake and limited target organ deposition,...
Adenovirus type B detection using the xxpress qPCR thermal cycler
Sep 17, 2018
The ultrafast xxpress qPCR thermal cycler through performing standard dilution series and multiplex qPCR experiments is...
Diagnosis of Acute Cellular Rejection Using Probe-Based Confocal Laser Endomicroscopy in Lung
Sep 3, 2018
Mauna Kea Technologies announced the publication of a prospective multicenter study that demonstrates the potential of...
Aug 9, 2018
We bring you the latest KOL interview on the Albira Si PET/SPECT/CT from Prof. John Prior, CHUV Lausanne. He describes...
Differentation displacement in acute myeloid leukemia through enhancer activation
Aug 7, 2018
Blast cell differentation is inhibitited by pharmacological targeting of lysine specific demethylase 1 (LSD1). In this...
Dynamic PET imaging and special focus in cardiac kinetic analysis
Aug 1, 2018
Micro-computed tomography, or micro-CT, is being employed by a rapidly increasing number of laboratories for bone...
Novel insights on the mechanical properties of IFs using LUMICKS’ technology
Jul 30, 2018
The journal Science Advances has recently published the paper ‘Viscoelastic properties of vimentin originate from...
Optical advances – the latest developments in Preclinical imaging
Aug 5, 2016
Preclinical in vivo molecular imaging is widely regarded as a key tool within the drug discovery and development pipeline, giving researchers clear visibility of cellular changes at a molecular level. Techniques – or modalities – such as optical, PET and SPECT imaging provide high specificity and wide applicability, as well as the ability to monitor several molecular events and identify key molecular markers. The result is a deeper understanding of disease progression, and the mode of action and pharmacokinetics of potential therapeutics.
If we consider small animal optical imaging systems specifically, these now enable researchers to combine a number of imaging modalities using the same instrument, thereby paving the way for a better understanding of physiological and disease mechanisms in the preclinical setting. For example, one such system provides five imaging modalities as standard, allowing for co-registration of molecular events with access to bioluminescence, multispectral VIS-NIR fluorescence, unique direct radioisotopic imaging, and Cerenkov radiation. A high speed digital X-ray scanner adds to the functional images with morphological features.
Related technologies: PET, SPECT, CT
Brand profile
